CurrentBlue Cross Blue Shield - MassachusettsPolicy 336

Genetic and protein biomarkers for prostate cancer diagnosis

This policy governs coverage and investigational status of genetic and protein biomarker tests used to assess prostate cancer risk, biopsy/referral decisions, and repeat biopsy decisions for Blue Cross Blue Shield - Massachusetts members.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyGenetic and protein biomarkers for prostate cancer diagnosis

Policy CodePolicy 336

Change TypeAnnual review (no material changes)

Effective DateN/A

Next Review DateN/A

Key ActionObtain precertification/preauthorization when services in this policy are performed inpatient.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

336internal policy id

1/2024last review

Investigational listinvestigational list

81539, 0021Ucodes mentioned

Multiple assaysreferenced tests

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Policy Position

Investigational for Commercial Members

Covered only when medical necessity for Medicare members is met for select tests; for Commercial members many listed biomarkers are considered investigational.

Investigational tests for Commercial members: The following biomarkers for the diagnosis of prostate cancer are considered INVESTIGATIONAL for Commercial members: Kallikrein markers (eg, 4Kscore Test); Autoantibodies (ARF6, NKX3-1, 5'-UTR-BMII, CEP164, 3'-UTR-Ropporin, Desmocollin, AURKAIP-); Prostate Health Index (phi); Single-nucleotide variant testing for cancer risk assessment.

From policy statement (Commercial members).

Medicare conditional coverage

Medicare-specific coverage condition for CPT code 81539.

Medicare coverage condition: The medical necessity criteria MUST be met for code 81539 to be covered for Medicare HMO Blue and Medicare PPO Blue.

Code-specific conditional coverage for Medicare members.

For outpatient services described in this policy, Commercial Managed Care (HMO and POS) and Commercial PPO/Indemnity outpatient products are noted as not a covered service in those product lines. Providers should verify member contract benefits at the time of service to determine coverage for an individual member; inclusion or exclusion of a code in the policy does not guarantee coverage or reimbursement.

Within the reference sections cited by this policy there are no additional explicit coverage exclusions beyond those noted for specific outpatient commercial products.

The evidence review found that, for both initial and repeat prostate biopsy decision-making, available studies are primarily observational and heterogeneous and do not provide direct evidence of clinical utility. Therefore, the evidence is insufficient to determine that genetic and protein biomarker tests improve net health outcomes when used to select patients for initial or repeat prostate biopsy.

No explicit statements labeled "not medically necessary" are present in the referenced sections of the document.

Coding and Regulatory Identifiers

Investigational CPT Codes (Commercial Members)CPTNot Covered

0021U

Oncology (prostate), detection of 8 autoantibodies (ARF6, NKX3-1, 5'-UTR-BMIT, CEP164, 3'-UTR-Ropporin, Desmocollin, AURKAIP-1, CSNKZA2), multiplexed

CPT Codes with conditional Medicare coverage / Investigational for CommercialCPT

81539

Oncology (high-grade prostate cancer); biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score

Regulatory identifiermixed

PMA P090026

FDA Premarket Approval summary for quantitative test for determination of [-2]proPSA levels

4Kscore diagnostic cutoffs (references)

Reported diagnostic cutoff range4Kscore cutoff values of 7.5% to 10% cited in meta-analysis and supporting literature

Study-level supportMeta-analysis and individual studies report 4Kscore cutoffs (eg, 7.5%) used to guide biopsy decisions with high sensitivity and NPV

Implication for practiceCutoffs in this range have been used in published literature to stratify biopsy risk, but the policy notes biomarkers lack standardized cutoffs

Provider Requirements and Prior Authorization

Prior Authorization

Prior Authorization Required

For services described in this policy, precertification/preauthorization IS REQUIRED for all products when the procedure is performed inpatient.

Preauthorization (precertification) required when performed inpatient.

Prior Authorization

Outpatient Prior Authorization / Coverage Note

For services described in this policy, outpatient prior authorization requirements vary by product. Some products list the service as not covered when performed outpatient (e.g., certain Commercial Managed Care HMO/POS and Commercial PPO/Indemnity product lines). Providers must verify member contract benefits at the time of service.

Commercial Managed Care (HMO and POS), Outpatient = This is not a covered service.
Commercial PPO and Indemnity, Outpatient = This is not a covered service.
Providers should verify benefit coverage for outpatient procedures prior to scheduling.

Clinical Background

Prostate cancer is clinically heterogenous, ranging from indolent tumors unlikely to affect life expectancy to aggressive, metastatic disease. Management options include active surveillance, surgery, radiation, hormonal therapy, and systemic chemotherapy. Biomarker tests (blood- or urine-based) have been developed to improve risk stratification and to help decide which men should undergo initial or repeat biopsy, but their performance characteristics, standardized cutoffs, and demonstrable impact on long-term clinical outcomes remain uncertain.

Test Definitions and Descriptions

Kallikrein panel / 4Kscore — description and intended use

DefinitionBlood-based panel measuring kallikrein markers (eg, total PSA, free PSA, intact PSA, hK2) reported as a probability score to predict high-grade prostate cancer

Clinical roleIntended to improve selection of men for initial prostate biopsy by estimating probability of high-grade disease

Coding noteMapped to CPT code 81539 (biochemical assay of four proteins reported as a probability score) with conditional Medicare coverage per policy

Prostate Health Index (phi) — assay description and role

DefinitionBiochemical assay incorporating proPSA and PSA measures intended to improve prediction of prostate cancer (combines total PSA, free PSA, and [-2]proPSA)

Clinical role

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyGenetic and protein biomarkers for prostate cancer diagnosis

Policy CodePolicy 336

Change TypeAnnual review (no material changes)

Effective DateN/A

Next Review DateN/A

Key ActionObtain precertification/preauthorization when services in this policy are performed inpatient.

SourceLink

On This Page

Note

Provider Actions

None specified. This section is reference-only and does not list additional provider actions beyond verification of member benefits and any product-specific prior authorization requirements.

Provider action: None specified in these reference-only sections.

Documentation Required

Coding and Documentation Guidance

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable. Inclusion or exclusion of a code in reference lists does not guarantee member coverage or provider reimbursement; verify the member's contract benefits.

Report services with current CPT/HCPCS/ICD codes and modifiers as applicable.
Inclusion/exclusion of a code does not imply coverage; confirm benefits.

Documentation Required

Regulatory Reference for Documentation

References include the Food and Drug Administration Summary of Safety and Effectiveness Data (PMA P090026) for proPSA and related regulatory materials.

FDA Summary of Safety and Effectiveness Data. PMA P090026 (proPSA).

Used to improve risk prediction for aggressive prostate cancer and to inform biopsy decision-making

Evidence noteSystematic reviews and observational studies report improved multivariable risk prediction but overall clinical utility is not definitively established

Prostate Health Index (PHI) — definition and FDA PMA

DefinitionPHI is a blood-based test combining total PSA, free PSA, and [-2]proPSA to estimate prostate cancer risk

Regulatory referenceFDA Summary of Safety and Effectiveness Data cited: PMA P090026 for quantitative determination of [-2]proPSA levels

Clinical validationReferenced in multiple studies and systematic reviews evaluating diagnostic accuracy and association with Gleason score/aggressiveness

PCA3 and TMPRSS2:ERG — urinary biomarkers

DefinitionPCA3 and TMPRSS2:ERG are urinary RNA biomarkers used alone or combined for individualized prostate cancer risk assessment and detection of aggressive disease

Clinical roleUsed to inform initial or repeat biopsy decisions by improving risk stratification beyond PSA alone

EvidenceMultiple studies evaluate incorporation of PCA3 and TMPRSS2:ERG into risk calculators and association with detection of aggressive cancer

ExoDx / ExoDx Prostate (EPI) — urine exosome gene expression assay

DefinitionExoDx Prostate (EPI) is a urine exosome gene expression assay developed to predict high-grade prostate cancer at initial biopsy

Clinical roleIntended to aid decision-making for initial biopsy in men with PSA in borderline range (eg, 2-10 ng/mL)

EvidenceProspective and validation studies (eg, JAMA Oncol 2016; Prostate Cancer Prostatic Dis. 2020) report diagnostic performance for high-grade disease

Epigenetic assays — DNA methylation-based tests

DefinitionEpigenetic assays evaluate DNA methylation or other epigenetic markers to predict occult or missed prostate cancer in histopathologically negative biopsies

Clinical roleUsed to inform repeat biopsy decisions by identifying men at higher risk of missed cancer despite negative biopsy

EvidenceClinical validation studies (eg, MATLOC, Partin et al.) and economic models suggest potential to reduce unnecessary repeat biopsies, but overall clinical utility remains under evaluation